- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
- SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences
- SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, SpringWorks Therapeutics Inc (SWTX:NSQ) closed at 42.95, -20.34% below its 52-week high of 53.92, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.85 |
---|---|
High | 43.98 |
Low | 42.67 |
Bid | 30.00 |
Offer | 50.40 |
Previous close | 42.95 |
Average volume | 1.17m |
---|---|
Shares outstanding | 74.09m |
Free float | 70.47m |
P/E (TTM) | -- |
Market cap | 3.18bn USD |
EPS (TTM) | -5.15 USD |
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
More ▼